In this podcast, we discuss a data-driven approach for optimizing congress planning and execution.
A position from MAPS on how Medical Affairs can optimize industry-led and independent Medical Education for maximum value and impact
Drawing on insights from a roundtable of industry leaders convened by Klick at the recent MAPS conference, let’s look at how viewing the KOL holistically can lead to new avenues of engagement and more multifaceted relationships.
In this podcast, we explore now that we appreciate the need to demonstrate impact and technologies exist that allow us to measure impact…what’s holding us back?
This webinar highlights the critical role of Medical Affairs in the healthcare industry.
Addressing the critical importance of integrating robust scientific understanding into the commercial journey, pinpointing the need for medical affairs to take the helm in defining and communicating the commercial value of healthcare innovations.
From the choice of where to publish to the assessment of impact, every decision holds weight in medical research publication. And yet, the metrics that have been traditionally used to guide these decisions offer only a partial view. The result: a hit-or-miss situation when it comes to reaching the target audience—healthcare professionals (HCPs) and patients. Can a data-driven approach that incorporates both traditional and the newer alternative metrics hold the key to improved publication planning, impact and thereby better patient outcomes?
MAPS has been educating and sharing expertise on genAI since ChatGPT first exploded onto the scene in early 2023. This year, as the dust settles, we focus on sharing the learnings from a year of pilots and projects to help others begin or accelerate their journey.
Remind yourself of key themes from the MAPS Madrid meeting with this Day 2 report authored by meeting media partner, the Publication Plan. If you weren’t able to attend this year’s meeting, catch up on what you missed!
In this podcast, we explore the origins of negative opinions of the pharmaceutical industry, and whether a for-profit model can support both innovation and the society’s best interests.